Navigation Links
CutisPharma Announces Issuance of a Patent for Suppository Compounding
Date:11/6/2008

US patent for the preparation, storage, and dispensing of compounded suppositories

WOBURN, Mass., Nov. 6 /PRNewswire/ -- CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,434,690) regarding a container and kit for the preparation, storage and dispensing of compounded suppositories.

"By its very nature, the process of compounding suppositories is cumbersome, time-consuming and in general, without adequate compensation" said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our container (suppository mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy. Our suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient dispensing tools", he added.

Currently CutisPharma has FIRST(R) Progesterone Vaginal Suppository Unit-of-Use Prescription Compounding Kit product line available, which uses the patented container. The line includes FIRST(R) - Progesterone VGS 25, 50, 100, 200 and 400 representing various strengths (mg.). The kits are made for a single patient and include pre-weighed progesterone, and suppository base, and the patented disposable container/mold for preparation, storage, and dispensing of the suppositories. A single NDC number assigned for the entire kit aids the third party reimbursement process, reduces audit- related adjustments, and the use of these FIRST(R) kits facilitates compliance with USP Chapter <795>. This patented container, kit, and the method will also be used for future suppository compounding kits such as Boric Acid, Morphine, and others.

CutisPharma estimates that over 1.5 million progesterone suppository prescriptions are written in the U.S. annually, representing a potential of nearly $100 million at the retail level. The Kit allows a pharmacy an easy entry into this market. The Company is experiencing a steady conversion from the conventional way to the FIRST(R) - way.

FIRST(R) products save dispensing time, are easy to use, and can be compounded by the pharmacist while the patient waits increasing customer satisfaction. Using FIRST(R) VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared by the traditional method using a metal suppository mold or polystyrene shells.

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at http://www.cutispharma.com/


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
2. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
3. Stereotaxis Announces New Management Appointment
4. SXC Health Solutions announces third quarter financial results
5. 360 Healthcare Staffing Announces Agreement With BlueSky Medical Staffing Software
6. Cardinal Health Announces Preliminary Shareholder Voting Results at Annual Meeting
7. Dialysis Corporation of America Announces $25 Million Credit Facility
8. Cornerstone Therapeutics Announces New Board of Directors
9. CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results
10. BD Announces Executive Appointments of President and Chief Financial Officer
11. BD Announces Results for Fourth Fiscal Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: